Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enhanced versus standard dermatologic management for skin adverse events during first-line amivantamab + lazertinib in EGFR-mutated NSCLC
2023-505863-35-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of amivantamab and lazertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Incidence of Grade >=2 dermatologic adverse events of interest in the first 12 weeks. Planned start Mar 2024; status: authorised.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505863-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505863-35-00.